Диссертация (1139465), страница 58
Текст из файла (страница 58)
168. – P. 691–696.271. Reichman, L.B. Why hasn’t BCG proved dangerous in HIV-infectedpatients? / L.B. Reichman // JAMA. – 1989. – Vol. 261. – P. 3246.272. Report on the Global AIDS Epidemic 2004. 4-th Global Report.- Geneva, 2004. - 24 p.273. Respiratory manifestations in HIV-infected children pre- and postHAART in Abidjan, the Ivory Coast / A.
Kouakoussui [et al.] // Paediatr. Respir.Rev. – 2004. - № 5. – P. 311–315.274. RET cell cytokine responses in persons with tuberculosis and humanimmunodeficiency virus infection / M. Zhang [et al.] // J. Clin. Invest. - 1994. –Vol. 94, № 6. – P.
2435-2442.275. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec. - 2007, May 25. – Vol. 82, № 21. – P. 193-196.276. Rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry BeirnCommunity Programs for Clinical Research on AIDS, the Adult AIDS ClinicalTrials Group, the Pan American Health Organization, and the Centers for DiseaseControl and Prevention Study Group / F.Gordin [et al.] // JAMA. – 2000.
– Vol.283. – P. 1445-1450.344277. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosisin HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group,the Pan American Health Organization, and the Centers for Disease Control andPrevention Study Group / F.Gordin[et al.] // J. Am. Med.
Assoc. – 2000. – Vol.283, № 11. – P. 1445-50.278. Rifampin preventive therapy for tuberculosis infection: experiencewith 157 adolescents / M.E. Villarino [et al.] //Am. J. оf Respiratory and CriticalCare Medicine. – 1997. – Vol. 155. – P. 1735-1738.279. Rifapentine and isoniazid once a week versus rifampicin and isoniazidtwice a week for treatment of drug-susceptible pulmonary tuberculosis in HIVnegative patients: a randomized clinical trial / D.
Benator [et al.] // Lancet. – 2002.– Vol. 360. – P. 528-534.280. Salim, S. Abdool Karim. Timing of Initiation of Antiretroviral Drugsduring Tuberculosis Therapy.). / Salim S. Abdool Karim [et al.] // N Engl. J Med2010; 362: 697-706;/ medmir.com нарусском.281. Safety and immunogenicity of bacillus Calmette-Guerin vaccine inchildren born to HIV-1 infected women / P. Thaithumyanon [et al.] // Southeast.Asian. J. Trop. Med.
Public. Health. - 2000. -№ 31. – P. 482–486.282. Sandra, V. Kik Improving the predictive value of interferon-gammarelease assays: do our methods go far enough? / V. Sandra // Int. J. Tuberc. Lung.Dis. – 2013. – Vol. 17, № 12, The Union. – P. 1516.283. Seibert, F.B. The isolation and properties of the purified protein derivative of tuberculin / F.B.
Seibert // Аmer. Rev. Tuberc. -1934. - Vol. 30. – P. 713720.284. Sensitivity of IFN-gamma release assay to detect latent tuberculosisinfection is retained in HIV-infected patients but dependent on HIV/ F. Karam [etal.] // PLoSOne. – 2008. – Vol.
3, № 1. – P. 1441.345285. Short course rifampin and pyrazinamide compared with isoniazid forlatent tuberculosis infection: a multicenter clinical. trial. / R.M. Jasmer [et al.]//Ann. Int. Med. – 2002. – Vol. 137. – P. 640-647.286. Small, P.M. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection / P.M. Small / /New End. J. Med. -1991. Vol.
324. - P. 289-292.287. Starke, J.R. Diagnosis of tuberculosis in children / J.R. Starke // Pediatr. Infect. Dis. J. - 2000. - № 19. – P. 1095-1096.288. Suchindran, S. Is HIV infection a risk factor for multidrug-resistanttuberculosis? A systematic review / S. Suchindran, E.S. Brouwer, A. Van Rie //PLoSONE. – 2009. - № 4.289. Surkova, L.A. Tuberculosis unrevealed during lifetime / L. Surkova ,Mi. Dziusmikeyeva, A.
Zalutskaya // Europ. Respir. J. - 2006. – Vol. 28. - Suppl.50. – P. 242.290. Surveillance of anti-tuberculosis drug resistance amongst childrenfrom the Western Cape Province of South Africa - an upward trend / H.S. Schaaf[et al.] // Am. J. Public. Health. – 2009. – Vol. 99. – P. 1486–1490.291. Targeted tuberculin testing and treatment of latent tuberculosis infection / Centers for Disease Control and Prevention // MMWR.
– 2002. – Vol. 49,RR-6. – P 454-459.292. Textbook of Pediatric Infectious Diseases / J.R. Starke [et al.].- 4thedn. – Philadelphia: W.B. Saunders Co.,1998. – P. 1196–239.293. The heparin binding haemagglutinin of M. tuberculosis is required forextrapulmonary dissemination / K. Pethe [et al.] // Nature. - 2001. – Vol.412(6843). – P.
190–194.294. The Italian Multidrug-Resistant Tuberculosis Outbreak Study Group.An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients346from two hospitals in Milan, Italy / M.L. Moro [et al.] // AIDS. – 1998. – Vol. 12. P. 1095 – 1102.295. The role of BCG vaccine in the prevention and control of Carneiro,I.A.M., Milstien, J.B. & Clements, C.J. Issues relating to the use of BCG in immunization programs / Centers for Disease Control and Prevention.
Report No.:WHO/V&B/99.23. – Geneva: World Health Organization, 1999.296. Treating opportunistic infections among HIV-exposed and infectedchildren. Recommendations from CDC, the National Institutes of Health fund theinfections Diseases Society of America. MMWR. Recommendations and reports //Morbidity and Mortality Weekly Report. – 2004. – Vol. 53 (RR-14). – P. 1-63.297.
Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy / F.S. Dossary Al [et al.] // Pediatr. Infect. Dis. J. – 2002. - Vol. 21, № 2. – Р. 91-97.298. Treatment of latent tuberculosis infection in HIV infected persons / С.Akolo[etal.] // Cochrane Database of Systematic Reviews.– 2010. - № 1. – Р. 8791. CD000171299. Treatment of tuberculosis in HIV- infected persons in the era of highlyactive antiretroviral therapy / G.L. Dean [et al.] // AIDS.
– 2002. – Vol. 16. – P.75-83.300. Tuberculin skin test reactivity among adults infected with human immunodeficiency virus / M.P. Johnson [et al.] // J. Infect. Dis. –1992. – Vol. 166. –P. 194-198.301. Tuberculosis exposure in HIV-exposed infants in a high-prevalencesetting / M.F. Cotton [ et al.] // Int. J. of Tuberc. and Lung Dis. – 2008. – Vol. 12,№ 2.
– P. 225-227.302. Tuberculosis in Argentinean HIV-infected children: analysis of a decade / A. Fallo[ et al.].: 39th Annual Meeting, IDSA2001. Arlington, VA// Infectious Diseases Society of America, 2001: Abstract . – Vol. 788. – P. 745-749.347303. Tuberculosis in children infected with human immunodeficiency virus: a report of five cases / W.J. Moss [et al.] // Pediatr. Infect.
Dis. J. – 1992. –Vol. 11, № 2. – P. 114-116.304. Tuberculosis in human immunodeficiency virus-infected children. Afamily infection. / S.S. Bakshi [et al.] // Am. J. Dis. Child. – 1993. – Vol. 147, №3. – P. 320-324.305. Tuberculosis in the United States // MMWR 45: RR-4. - 1996. - Fine,R.E.M. – P.
65–67.306. Tuberculosis in children / D.E. Snider [et al.] // Pediatr. Infect. Dis. J.-1988. – P. 149-151.307. Twice weekly tuberculosis preventive therapy in HIV infection inZambia / A. Mwinga [et al.] // AIDS. – 1998. – Vol. 12. – P. 2447-2457.308. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women / S. Allen [et al.] // Am. Rev. Respir.
Dis. – 1992.– Vol. 146. - P. 1439-1444.309. UNAIDS. Report on the global HIV/AIDS epidemic, June 2000.UNAIDS. - Geneva, 2000. – 46 c.310. UNZA-UCLMS Project Pediatric Post-mortem Study Group, Lungdiseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study / C. Chintu [et al.] // Lancet. – 2002, Sep.
28. – Vol. 360, №9338. – P. 985-90.311. Update: fatal and severe liver injuries associated with rifampin andpyrazinamide for latent tuberculosis infection, and revisions in American ThoracicSociety : CDC recommendations / Centers for Disease Control and Prevention,United States, 2001 // MMWR. – 2001. - Vol. 50, № 34. – P. 345-348.312. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease348inhibitors or non-nucleoside reverse transcriptase inhibitors / Centers for DiseaseControl and Prevention // MMWR. – 2000.
– Vol. 49, № 9. – P. 452-455.313. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study /G.Ferrara [et al.] // Lancet. - 2006. - № 367. –P. 1328-1334.314. Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program / D.H. Priest [et al.] //Clin.
Infec.t Dis. – 2004. – Vol. 39. – P. 1764-1771.315. Use of rifabutin with protease inhibitors for human immunodeficiencyvirus-infected patients with tuberculosis / M. Narita // Clin.-Infect.-Dis. – 2000,May. –Vol. 30, № 5. - P.779-783.316. Vallejo, J.G. Clinical features, diagnosis and treatment of tuberculosisin infants / J.G. Vallejo, L.T. Ong, J.R.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
